![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C
JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C
June 30, 2006
Johnson & Johnson announced today that Janssen Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals Incorporated to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950. Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=410842)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct